Navigation Links
Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Date:9/24/2009

"non-culprit" lesions of the three-vessel coronary tree. Half of the patients treated for non-culprit events exemplified the classic notion of vulnerable plaque.

The event rate, particularly that attributed to vulnerable plaques specifically, was lower than expected. Further, patients who experienced "non-culprit" events in the years following PCI were more likely to present with progressive or unstable angina, and rarely with cardiac death, arrest or MI. Imaging of the lesions that did progress to events suggests that vulnerable plaque lesions with a large plaque burden and large necrotic core without a visible cap were at especially high risk for future adverse cardiovascular events.

"Abbott's PROSPECT trial is the most comprehensive study ever done on vulnerable plaque and the results shed new light on understanding its role in the progression of coronary artery disease," said John M. Capek, executive vice president, medical devices, Abbott. "As a leader in cardiovascular devices, diagnostics and medicines, Abbott looks forward to sharing these results with the vascular community and adding to our understanding of the disease."

About the PROSPECT Trial

Abbott's PROSPECT trial is the first prospective natural history study to examine the role of vulnerable plaque and how it might progress to a cardiac event. PROSPECT used novel intravascular imaging technology to correlate plaque characteristics, patient risk factors and biomarker measurements with subsequent heart attacks and other cardiac events, potentially paving the way for physicians to identify and treat at-risk patients before a heart attack occurs.

PROSPECT enrolled 700 patients from 40 clinical centers across the United States and Europe. All patients received PCI for acute coronary syndrome (ACS), which included unstable angina, NSTEMI or STEMI. Patient follow up continued for three years. Abbott sponso
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 Elekta (NSE:EKTAb) and ... The Christie NHS Foundation Trust ( Manchester, UK ... consortium whose mission is to develop the clinical value ... therapy system. Such a system would, in principle, improve ... targets. "The Christie was an essential ...
(Date:7/22/2014)... 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), a ... and healthcare products, announced today that the company ... "We are pleased to sponsor Operation ... and Chairman of PuraMed BioScience. "Research shows that ... experience migraines much more frequently than the general ...
(Date:7/22/2014)...  July 22, 2014 The ... Reuters , the world,s leading provider of ... announced Cortellis Clinical Trials Intelligence , ... industry-first milestone with the documentation of more ... professionals with greater and quicker access to ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3
... Dec. 7, 2010 LABS Inc., the premier transplant ... that Kevin M. Smith, Chief Operating Officer of the ... has joined the company,s Board of Directors.  Smith brings ... industries. In addition to his current role ...
... 80 percent of the surgeries performed in the U.S. put patients ... a brain monitor is not used by the anesthesiologist. ... book recently published by Dr. Barry Friedberg, an acclaimed anesthesiologist who ... in Michael Jackson,s death. "The simple use of a ...
Cached Medicine Technology:LABS Inc. Adds Life Sciences Industry Veteran Kevin M. Smith to Board of Directors 2Michael Jackson's Death Could Have Been Avoided With a Brain Monitor Says Anesthesiologist 2
(Date:7/22/2014)... Dr. Dental is excited to announce the redesign of ... mind, one of the main differences from the old website ... very easy. Dr. Dental is renowned for having exceptional customer ... affordable, convenient and fun, and the new website mirrors these ... scheduling system right on the home page where a visitor ...
(Date:7/22/2014)... United Benefit Advisors (UBA), the nation's ... McPhearson, an insurance veteran with more than 15 years ... be based in the company's Chicago office. , UBA ... Les chose to accept this important, strategic position with ... many challenges facing UBA and its Partners as we ...
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... that break up blood clots deep in the veins of ... However, one results in a greater risk of bleeding and ... the other treatment, a new study finds. The standard ... (DVT) -- is blood-thinning medications and compression stockings. The other, ...
(Date:7/22/2014)... of Hematology (ASH) will honor Michael DeBaun, MD, MPH, ... Hebbel, MD, of the University of Minnesota Medical School ... their significant research advances in the area of sickle ... the late Ernest Beutler, MD, a past president of ... a two-part lectureship that recognizes major translational advances related ...
(Date:7/22/2014)... E. Marc, Ph.D., director of research at the University ... named by the International Society of Eye Research (ISER) ... Foundation,s 2014 Paul Kayser International Award in Retina Research., ... who has made a significant contribution to the understanding ... presented this week at the ISER Biennial Meeting in ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Fishies is Nordic Naturals newest product for children, the "ultimate ... tasting natural tangerine flavor. Perfect for two-year-olds and up, Nordic ... oil from anchovies and sardines, two sustainable sources of high ... 455 mg of fish oil and offers 136 mg of ...
... Jourdan Urbach, a senior at Roslyn High School, is at ... only 12 seniors nationwide to be named a "national" Toyota Community ... than 8,000 seniors from across the country were nominated by their ... year, honors the top 100 students in the U.S. who are ...
... 23 The European diabetes diagnostics market is poised ... (POC) tests offering tremendous growth potential. Heightened efforts to ... a key driver in market development. For instance, limited ... However, this challenge will be curtailed with more education ...
... ... for the Study of Subtle Energies & Energy Medicine will hold their 19th annual conference ... ... professionals will be interested in attending the 19th annual ISSSEEM Conference that will begin with ...
... ... , ... 23, 2009 -- Big Case Marketing, the global leader in marketing for dentists, dental marketing ... a Boston based coaching and consulting firm for dentists with advanced clinical training, has announced ...
... Dr. Steven Shoshany ... www.LivingwellNewYork.com , to coincide with an exciting new direction he is taking with his office ... ... Chiropractic care in New York City for more than 13 years in his SOHO office. He ...
Cached Medicine News:Health News:Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with 'Kid Pleasin' Taste 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 2Health News:Toyota Awards $1 Million in Scholarships to 100 High School Seniors - Roslyn High's Urbach Named One of Only 12 'National' Winners; Receives $20,000 3Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 2Health News:Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market 3Health News:19th Annual ISSSEEM Conference to Have Richard Bartlett to Discuss the Physics of Miracles: Connecting to the Quantum Field 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:New York City Chiropractor Announces New State-Of-The-Art Facility, Website 2
Calcitonin RIA Kit...
... 1200's speed and accuracy allow clinical ... a timely manner - something everyone ... patients. In fact, the Rapidlab 1200 ... just one minute. Its maintenance-free, cartridge-based ...
... The Dornier Medilas D Fibertom is a 60 ... nm wavelength. The use of Diode Power Bar ... system ideal for endovenous laser treatment for varicose ... Medilas D Fibertom also includes unique safety features ...
... test studies the characteristic axies of ... however this 28 hue test ... Case comes with a transparent base ... includes laminated scoring template (approx 8 ...
Medicine Products: